Silent corticotroph adenomas: Emory university cohort and comparison with acth-negative nonfunctioning pituitary adenomas

Neurosurgery

Volumn 71, Issue 2, 2012, Pages 296-303

  Ioachimescu, Adriana G ^a,b   Eiland, Leslie ^a   Chhabra, Vaninder S ^b   Mastrogianakis, Gena M ^b   Schniederjan, Matthew J ^b   Brat, Daniel ^b   Pileggi, Anthony V ^c   Oyesiku, Nelson M ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Neurological Surgery ^*  (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Corticotroph adenomas; Corticotropin; Nonfunctioning pituitary adenoma; Surgical outcomes; Transsphenoidal surgery

Indexed keywords

CORTICOTROPIN;

ACTH SECRETING ADENOMA; ADJUVANT THERAPY; ADULT; AGED; CANCER INVASION; CAVERNOUS SINUS; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DEATH; DIABETES INSIPIDUS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOTHYROIDISM; INCIDENTALOMA; INTERMETHOD COMPARISON; LONG TERM CARE; MALE; NEUROSURGEON; NONFUNCTIONING PITUITARY ADENOMA; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; REVIEW; SILENT CORTICOTROPH ADENOMA; SURVIVAL RATE; TERTIARY HEALTH CARE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ADRENOCORTICOTROPIC HORMONE; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84864279792     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e318257c1f0     Document Type: Review

References (27)

1. Kovacs K, Horvath E, Bayley TA, Hassaram ST, Ezrin C. Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. A distinct clinicopathologic entity. Am J Med. 1978;64(3):492-499.
2. Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W. Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol. 1980;98(3):617-638.
3. Scheithauer BW, Jaap AJ, Horvath E, et al. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery. 2000;47(3):723-729; discussion 729-730.
4. Webb KM, Laurent JJ, Okonkwo DO, LopesMB, Vance ML, Laws ER Jr. Clinical characteristics of silent corticotrophic adenomas and creation of an internetaccessible database to facilitate their multi-institutional study. Neurosurgery. 2003;53 (5):1076-1084; discussion 1084-1085.
5. Cho HY, Cho SW, Kim SW, Shin CS, Park KS, Kim SY. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf). 2010;72(5): 648-653.
6. Bradley KJ, Wass JA, Turner HE. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf). 2003;58(1):59-64.
7. Baldeweg SE, Pollock JR, Powell M, Ahlquist J. A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg. 2005;19(1):38-42.
8. Lopez JA, Kleinschmidt-Demasters B, Sze CI, Woodmansee WW, Lillehei KO. Silent corticotroph adenomas: further clinical and pathological observations. Hum Pathol. 2004;35(9):1137-1147.
9. Scheithauer BW, Gaffey TA, Lloyd RV, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006;59(2):341-353; discussion 341-353.
10. Farrell WE, Coll AP, Clayton RN, Harris PE. Corticotroph carcinoma presenting as a silent corticotroph adenoma. Pituitary. 2003;6(1):41-47.
11. Moshkin O, Syro LV, Scheithauer BW, et al. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones (Athens). 2011;10(2):162-167.
12. Roncaroli F, Scheithauer BW, Young WF, et al. Silent corticotroph carcinoma of the adenohypophysis: a report of five cases. Am J Surg Pathol. 2003;27(4): 477-486.
13. Gibson S, Ray DW, Crosby SR, et al. Impaired processing of proopiomelanocortin in corticotroph macroadenomas. J Clin Endocrinol Metab. 1996;81(2): 497-502.
14. Ohta S, Nishizawa S, Oki Y, Yokoyama T, Namba H. Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I-immunohistochemical study. Pituitary. 2002;5(4): 221-223.
15. Raverot G, Wierinckx A, Jouanneau E, et al. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol. 2010; 163(1):35-43.
16. Tateno T, Izumiyama H, Doi M, Akashi T, Ohno K, Hirata Y. Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma. Endocr J. 2007;54(5):777-782.
17. Reincke M, Allolio B, Jaursch-Hancke C, Kaulen D, Winkelmann W. Adrenostatic treatment of ACTH-dependent Cushing syndrome using metyrapone and aminoglutethimide [in German]. Dtsch Med Wochenschr. 1987;112(40): 1532-1535.
18. Jin L, Riss D, Ruebel K, et al. Galectin-3 expression in functioning and silent ACTH-Producing adenomas. Endocr Pathol. 2005;16(2):107-114.
19. Thodou E, Argyrakos T, Kontogeorgos G. Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens). 2007;6(3): 227-232.
20. Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010;1(2):80-92.
21. Cooper ME, Murray RM, Kalnins R, Woodward J, Jerums G. The development of Cushing's syndrome from a previously silent pituitary tumour. Aust N Z J Med. 1987;17(2):249-251.
22. Gogel EL, Salber PR, Tyrrell JB, Rosenblum ML, Findling JW. Cushing's disease in a patient with a 'nonfunctioning' pituitary tumor. Spontaneous development and remission. Arch Intern Med. 1983;143(5):1040-1042.
23. Vaughan NJ, Laroche CM, Goodman I, Davies MJ, Jenkins JS. Pituitary Cushing's disease arising from a previously non-functional corticotrophic chromophobe adenoma. Clin Endocrinol (Oxf). 1985;22(2):147-153.
24. Petrossians P, Ronci N, Valdés Socin H, et al. ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol. 2001;144(1):51-57.
25. Gabalec F, Beranek M, Netuka D, et al. Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas [published online ahead of print]. Pituitary. 2011.
26. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J. 2009;56(4):579-584.
27. Salehi F, Scheithauer BW, Kovacs K, et al. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas. Neurosurgery. 2012;70(2):491-496.